Absci Corporation is a clinical-stage biopharmaceutical company that uses a generative-AI "Integrated Drug Creation" platform to design antibody therapeutics. Its analyst coverage skews heavily bullish, with the large majority of firms rating the shares Buy, Overweight, or Outperform and only a handful at Hold.
Verified individual targets reviewed include $20 from KeyBanc (October 2026), $17 from Truist, $16 from H.C. Wainwright and BTIG, $15 from J.P. Morgan and Guggenheim, $14 from Jefferies (initiation), $13 from JonesTrading, $12 from Leerink Partners, $11 from Needham, and $10 from Morgan Stanley. Averaging these yields a mean near $14.50, which rounds to the $15 central target used here. The low-to-high range of roughly $10 to $20 is unusually wide, underscoring how sensitive these estimates are to assumptions about pipeline value.
Bullish analysts emphasize positive interim Phase 1 safety and pharmacokinetic data for ABS-201, its lead candidate for androgenetic alopecia (hair loss) and endometriosis, plus the de-risking effect of a $100 million equity offering in which Eli Lilly participated. More cautious voices, such as Morgan Stanley's $10 Hold target, reflect that the pipeline has not yet produced human proof of concept. These are analyst expectations, not guarantees.
ABSI has been highly volatile, moving within a 52-week range of roughly $2.24 to $12.55 and recently trading near $9.67 after a prior close near $10.12. Reaching the $15 target implies upside of about 55%, a substantial move for a company that remains unprofitable.
The path would likely depend on clinical execution rather than current fundamentals. Revenue is minimal — roughly $215,000 in the most recent reported quarter — and the company reports a negative EPS (earnings per share) while funding a growing research organization. Any sustained move toward $15 would most plausibly be driven by positive data from Phase 1 or Phase 2 readouts for ABS-201 and ABS-101, progress on partnerships, or renewed enthusiasm for AI-enabled drug discovery, rather than near-term earnings.
The stock's 52-week low near $2.24 and high near $12.55 define a wide trading range following a powerful 2026 rally. The $12–$13 zone, which includes the recent 52-week high, represents a key resistance level that would likely need to be cleared before a move toward $15. On the downside, the $8–$9 area has served as a notable support level during recent consolidations. The $15 target sits above the stock's all-time-high region, meaning the move would require a fresh breakout rather than a return to prior levels.
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may apply different timelines and methodologies. Investors should monitor upcoming Phase 1 and Phase 2 data readouts for ABS-201 and ABS-101, quarterly earnings and cash-position updates, any further analyst target revisions, and whether strategic partners such as Eli Lilly or AMD deepen their involvement. Regulatory milestones and sector-wide sentiment toward AI drug discovery also matter.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like ABSI, these signals can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening. Explore the signals to see how AI is interpreting the current market environment.
Can Absci Corporation (ABSI) reach $15? The target is a legitimate average of verified analyst price targets, and it sits roughly 55% above recent trading levels. The strongest supports are clinical momentum, strategic backing from Eli Lilly and AMD, and a wave of upward target revisions. The principal obstacles are the absence of human efficacy data, ongoing losses, and a valuation that leaves little room for disappointment. With targets spanning $10 to $20, analysts themselves disagree sharply about how much the pipeline is worth. Reaching $15 would require clinical success and sustained investor conviction; it is a possibility, not a forecast. Watch the next data readouts, cash updates, and analyst revisions for the clearest signal of direction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ABSI has been loosely correlated with CRSP. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ABSI jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To ABSI | 1D Price Change % | ||
|---|---|---|---|---|
| ABSI | 100% | +1.40% | ||
| CRSP - ABSI | 61% Loosely correlated | -0.54% | ||
| RXRX - ABSI | 61% Loosely correlated | -6.37% | ||
| BEAM - ABSI | 57% Loosely correlated | -1.38% | ||
| ABCL - ABSI | 57% Loosely correlated | -0.81% | ||
| SANA - ABSI | 53% Loosely correlated | N/A | ||
More | ||||